A previous investigation established that MYPT1 functions as a direct target of microRNA‐30d [12], suppresses angiogenesis, and is related to an improved prognosis in individuals with PCa, illustrating that MYPT1 could be a possible candidate drug for treating cancer [13]. Here, PPP1R12A is linked to posterior cortical atrophy.